Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy

  • Camarero-Hoyos, Claudia
  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen|||0000-0003-4074-5624
  • Fallica, Antonino Nicolò|||0000-0003-1899-8414
  • Román-Álamo, Lucía
  • Ramírez Moreno, Miriam|||0000-0002-9823-319X
  • Portabella, Emma
  • Cuspinera, Ona
  • Currea-Ayala, Daniela
  • Orozco-Quer, Marc
  • Ribera, Maria
  • Siden-Kiamos, Inga|||0000-0003-1572-5840
  • Spanos, Lefteris
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Crespo, Benigno
  • Viera, Sara|||0000-0002-2025-4804
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Zarzuela, Francesc
  • Urtasun, Nerea|||0000-0003-1093-2269
  • Pérez-Torras, Sandra|||0000-0002-2785-5602
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Arce, Elsa M.|||0000-0003-3757-5468
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
Background/Objectives : YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results : The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug's mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions : Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

  • Pont, Caterina|||0000-0001-9118-0892
  • Sampietro, Anna|||0000-0002-1837-2051
  • Pérez-Areales, Francisco Javier|||0000-0001-9525-9346
  • Cristiano, Nunzia
  • Albalat, Agustí
  • Pérez, Belén|||0000-0001-5801-1704
  • Bartolini, Manuela|||0000-0002-2890-3856
  • De Simone, Angela|||0000-0003-1915-458X
  • Andrisano, Vincenza|||0000-0003-4396-1904
  • Barenys, Marta
  • Teixido, Elisabet|||0000-0002-0146-876X
  • Sabaté Lagunas, Raimon|||0000-0003-3894-2362
  • Loza García, María Isabel
  • Brea, José|||0000-0002-5523-1979
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
Multitarget compounds have emerged as promising drug candidates to cope with complex multifactorial diseases, like Alzheimer's disease (AD). Most multitarget compounds are designed by linking two pharmacophores through a tether chain (linked hybrids), which results in rather large molecules that are particularly useful to hit targets with large binding cavities, but at the expense of suffering from suboptimal physicochemical/pharmacokinetic properties. Molecular size reduction by removal of superfluous structural elements while retaining the key pharmacophoric motifs may represent a compromise solution to achieve both multitargeting and favorable physicochemical/PK properties. Here, we report the stepwise structural simplification of the dihydroxyanthraquinone moiety of a rhein-huprine hybrid lead by hydroxy group removal-ring contraction-ring opening-ring removal, which has led to new analogs that retain or surpass the potency of the lead on its multiple AD targets while exhibiting more favorable drug metabolism and pharmacokinetic (DMPK) properties and safety profile. In particular, the most simplified acetophenone analog displays dual nanomolar inhibition of human acetylcholinesterase and butyrylcholinesterase (IC = 6 nM and 13 nM, respectively), moderately potent inhibition of human BACE-1 (48% inhibition at 15 µM) and Aβ42 and tau aggregation (73% and 68% inhibition, respectively, at 10 µM), favorable in vitro brain permeation, higher aqueous solubility (18 µM) and plasma stability (100/96/86% remaining in human/mouse/rat plasma after 6 h incubation), and lower acute toxicity in a model organism (zebrafish embryos; LC » 100 µM) than the initial lead, thereby confirming the successful lead optimization by structural simplification.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synthesis of Diversely Substituted Diethyl (Pyrrolidin-2-Yl)Phosphonates

  • Bagán, Andrea
  • López-Ruiz, Alba
  • Abás, Sònia|||0000-0002-3005-3539
  • Molins Grau, Elies|||0000-0003-1012-0551
  • Pérez, Belén|||0000-0001-5801-1704
  • Muneta-Arrate, Itziar
  • Callado, Luis F.|||0000-0001-9941-012X
  • Escolano, Carmen|||0000-0002-9117-8239
Imidazoline I receptors (I-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I-IR is limited. In this framework, we have reported several new structural families embodying the iminophosphonate functional group that have an excellent affinity and selectivity for I-IR, and selected members have demonstrated relevant pharmacological properties in murine models of neurodegeneration and Alzheimer's disease. Starting with these iminophosphonates, we continued to exploit their high degree of functionalization through a short and efficient synthesis to access unprecedented 2,3-di, 2,2,3-tri, 2,3,4-tri, and 2,2,3,4-tetrasubstituted diethyl (pyrrolidine-2-yl) phosphonates. The stereochemistry of the new compounds was unequivocally characterized by X-ray crystallographic analyses. Two selected compounds with structural features shared with the starting products were pharmacologically evaluated, allowing us to deduce the required key structural motifs for biologically active aminophosphonate derivatives.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Beta-hydroxybutyrate counteracts the deleterious effects of a saturated high-fat diet on synaptic AMPAR receptors and cognitive performance

  • Rojas, Rocío|||0000-0002-0509-1023
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Castellanos, Aida
  • Griego, Ernesto
  • Martínez, Marc
  • de Dios Navarro-López, Juan
  • Jiménez-Díaz, Lydia|||0000-0001-9121-0334
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Soto del Cerro, David
  • Castillo, Pablo E.
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Casals, Nuria|||0000-0002-6719-4300
  • Fadó, Rut|||0000-0002-3293-2342
The ketogenic diet -high in fat and low in carbohydrates- and intermittent fasting have gained popularity not only for weight management but also for their potential to delay cognitive decline associated with neurodegenerative diseases and aging. However, adherence to these diets remains low due to their restrictive nature and undesirable side effects. Both dietary approaches stimulate hepatic production of ketone bodies, primarily β-hydroxybutyrate (BHB), which serves as an alternative energy source for neurons. Here, we investigated whether BHB supplementation could mitigate AMPA receptor trafficking impairments, synaptic dysfunction, and cognitive decline induced by metabolic challenges such as a saturated fat-rich diet. Our results show that, in cultured primary cortical neurons, exposure to palmitic acid decreases surface levels of glutamate GluA1-containing AMPA receptors, whereas unsaturated fatty acids and BHB increase these levels. Furthermore, physiological concentrations of BHB (1-2 mM) countered the adverse effects of palmitic acid on synaptic GluA1 and GluA2 levels in hippocampal neurons, restoring AMPA receptor-mediated synaptic transmission. In hippocampal slices, BHB also reversed palmitate-induced impairments in excitability and synaptic plasticity (long-term potentiation; LTP). Additionally, daily intragastric administration of BHB (100 mg/kg/day for two months) prevented deficits in recognition and spatial memory induced by a saturated fat-rich diet (49% of calories from fat) in mice. In summary, our findings underscore the significant impact of fatty acids and ketone bodies on AMPA receptor abundance, synaptic function, and neuroplasticity, shedding light on the potential use of BHB as a dietary supplement to counteract cognitive impairments linked to metabolic diseases.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery

  • Gomez Sanchez, Jose
  • Leivar, Pablo
  • Pinto, Soraia
  • Almeida, Helena
  • Artigues Cladera, Margalida
  • Sarmento, Bruno
  • Lecina, Martí
  • Fornaguera, Cristina
Small extracellular vesicles (sEVs) are emerging as promising nanocarriers for non-invasive pulmonary drug delivery, yet their effectiveness is limited by sequential barriers imposed by airway mucus and the pulmonary epithelium-endothelium interface. Here, we investigated how post-secretory surface engineering with exogenous phospholipids modulates sEVs transport across lung-relevant barriers. eGFP-CD81 engineered sEVs were post-secretory modified at their surface composition using different lipid-to-vesicle ratios of either the zwitterionic lipid 1,2- Dilauroyl-sn-glycero-3-phosphocholine (DLPC) or the PEGylated lipid 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) -PEG(5000) - Azide (DPA). Both modifications enabled controlled tuning of surface charge and colloidal stability without altering vesicle size at optimized lipid-to-vesicle ratios, although excessive DPA induced aggregation. The physicochemical properties and transport behaviour of engineered sEVs were evaluated in a reconstituted mucin gel and a 3D pulmonary epithelial-endothelial co-culture model. In mucin-containing medium, lipid-engineered sEVs showed enhanced diffusion compared with unmodified vesicles, with DLPC at a 30,000:1 ratio providing the highest cumulative permeability, sustained apparent permeability coefficients, and more diffusive motion profiles, as confirmed by multiple particle tracking. In the 3D co-culture, the same modification achieved the greatest cumulative permeability and basolateral accumulation, indicating efficient transcellular passage, while DPA-functionalized vesicles displayed moderate permeability and predominant retention at the apical epithelial layer. Through fluorescently-labelling EVs, we confirmed that all formulations were internalized by apical cells, but only DLPC-engineered sEVs reached detectable levels in basolateral cells. Neither DLPC nor DPA affected cell viability or barrier morphology. Overall, our results identify DLPC at 30,000:1 as a lead formulation that balances mucus penetration and efficient crossing of the pulmonary barrier, while DPA is better suited for applications requiring strong epithelial engagement. Our findings highlight rational phospholipid engineering as a powerful approach to tailor sEVs-based nanomedicines for pulmonary delivery., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Covalent functionalization of polymeric nanoparticles prepared from nano-emulsion templates for gene silencing and antioxidant delivery at neuronal level

  • Bel Esteve, Marta
  • Carrasco, Marc
  • Moral, Nuria
  • Aviñó, Ana
  • Fàbrega, Carme
  • eritja, ramon
  • del Río, José Antonio
  • Duran, Jordi
  • Fornaguera, Cristina
  • Rodriguez-Abreu, Carlos
  • Grijalvo, Santiago
Poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles (PLGA NPs) have proven to be effective as potential drug delivery systems. The presence of carboxylate groups on their surface facilitates the development of multifunctional NPs enhancing therapeutic efficacy through synergetic effects. Our study describes the preparation of PLGA NPs using oil-in-water polymeric nano-emulsions, generated via a phase inversion composition low-energy emulsification method. Rosmarinic acid (RA), a phytochemical with neuroprotective effects, and an antisense oligonucleotide (ASO) were selected respectively as a phytochemical to be entrapped and as a ligand to decorate the surface of PLGA nanoparticles respectively, aiming to enhance ASO delivery to neuronal cells. Physicochemical characterization confirmed that RA and ASO incorporation preserved colloidal stability, with no adverse effect on particle size, surface charge, or morphology. In vitro-controlled release experiments showed a cumulative RA release of ca. 12% over 24 h governed by a semi-Fickian diffusion mechanism after adjusting to different equation models. Importantly, RA entrapment displayed measurable radical scavenging capacity, leading to a EC50 of 76 ± 0.9 μg·mL−1. Cell culture experiments confirmed biocompatibility in both a non-cancer cell line (HEK293) and neuroblastoma cell model (SH-SY5Y). Uptake studies revealed efficient internalization of PLGA NPs by SH-SY5Y cells and primary murine neurons, promoting gene silencing of luciferase expression (53.7 ± 7.9%). Together, these results show a modular PLGA nanoplatform that enables the simultaneous incorporation of an antioxidant payload and a covalently grafted antisense oligonucleotide, allowing independent assessment of redox modulation and gene silencing in neuronal models., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Engineering oncogene-targeted anisamide-functionalized pBAE nanoparticles as efficient lung cancer antisense therapies

  • Fornaguera, Cristina
  • Torres-Coll, Antoni
  • Olmo, Laura
  • Garcia-Fernandez, Coral
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
Non-small cell lung cancer (NSCLC) is one of the leading causes of worldwide death, mainly due to the lack of efficient and safe therapies. Currently, NSCLC standard of care for consist on the use of traditional chemotherapeutics, non-selectively distributed through the whole body, thus causing severe side effects while not achieving high efficacy outcomes. Consequently, the need of novel therapies, targeted to modify specific subcellular routes aberrantly expressed only in tumor cells is still urgent. In this context, the delivery of siRNAs that can know-down overexpressed oncogenes, such as mTOR, could become the promised targeted therapy. However, siRNA effective delivery remains a challenge due to its compromised stability in biological fluids and its inability to cross biological and plasmatic membranes. Therefore, polymeric nanoparticles that efficiently encapsulate siRNAs and are selectively targeted to tumor cells could play a pivotal role. Accordingly, we demonstrate in this work that oligopeptide end-modified poly(beta aminoester) (OM-pBAE) polymers can efficiently complex siRNA in small nanometric particles using very low polymer amounts, protecting siRNA from nucleases attack. These nanoparticles are stable in the presence of serum, advantageous fact in terms of in vivo use. We also demonstrated that they efficiently transfect cells in vitro, in the presence of serum and are able to knock down target gene expression. Moreover, we demonstrated their antitumor efficacy by encapsulating mTOR siRNA, as a model antisense therapy, which showed specific lung tumor cell growth inhibition in vitro and in vivo. Finally, through the addition of anisamide functionalization to the surface of the nanoparticles, we proved that they become selective to lung tumor cells, while not affecting healthy cells. Therefore, our results are a first step in the discovery of a tumor cell-targeted efficient silencing nanotherapy for NSCLC patients survival improvement., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery

  • Gomez Sanchez, Jose
  • Leivar, Pablo
  • Pinto, Soraia
  • Almeida, Helena
  • Artigues Cladera, Margalida
  • Sarmento, Bruno
  • Lecina, Martí
  • Fornaguera, Cristina
Small extracellular vesicles (sEVs) are emerging as promising nanocarriers for non-invasive pulmonary drug delivery, yet their effectiveness is limited by sequential barriers imposed by airway mucus and the pulmonary epithelium-endothelium interface. Here, we investigated how post-secretory surface engineering with exogenous phospholipids modulates sEVs transport across lung-relevant barriers. eGFP-CD81 engineered sEVs were post-secretory modified at their surface composition using different lipid-to-vesicle ratios of either the zwitterionic lipid 1,2- Dilauroyl-sn-glycero-3-phosphocholine (DLPC) or the PEGylated lipid 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) -PEG(5000) - Azide (DPA). Both modifications enabled controlled tuning of surface charge and colloidal stability without altering vesicle size at optimized lipid-to-vesicle ratios, although excessive DPA induced aggregation. The physicochemical properties and transport behaviour of engineered sEVs were evaluated in a reconstituted mucin gel and a 3D pulmonary epithelial-endothelial co-culture model. In mucin-containing medium, lipid-engineered sEVs showed enhanced diffusion compared with unmodified vesicles, with DLPC at a 30,000:1 ratio providing the highest cumulative permeability, sustained apparent permeability coefficients, and more diffusive motion profiles, as confirmed by multiple particle tracking. In the 3D co-culture, the same modification achieved the greatest cumulative permeability and basolateral accumulation, indicating efficient transcellular passage, while DPA-functionalized vesicles displayed moderate permeability and predominant retention at the apical epithelial layer. Through fluorescently-labelling EVs, we confirmed that all formulations were internalized by apical cells, but only DLPC-engineered sEVs reached detectable levels in basolateral cells. Neither DLPC nor DPA affected cell viability or barrier morphology. Overall, our results identify DLPC at 30,000:1 as a lead formulation that balances mucus penetration and efficient crossing of the pulmonary barrier, while DPA is better suited for applications requiring strong epithelial engagement. Our findings highlight rational phospholipid engineering as a powerful approach to tailor sEVs-based nanomedicines for pulmonary delivery., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sleep-Related and Chronobiology Traits and Health-Related Phenotypes: A Phenome-Wide Mendelian Randomisation Study

  • HERNANDEZ, MARTA
  • Lassale, Camille
  • Camps-Vilaró, Anna
  • Fernández Sanlés, Alba
  • Polo-Alonso, Sara
  • Huertas, Marta
  • Hernando Redondo, Javier
  • Fornara, Eleonora
  • Carrillo Álvarez, Elena
  • Zeron-Rugerio, Maria Fernanda
  • Izquierdo Pulido, María
  • Gil Vives, Maria
  • Fornaguera, Cristina
  • Hernáez, Álvaro
Sleep-related and chronotype traits have been shown to impact health in observational studies. To identify whether these associations are potentially causal, we conducted phenome-wide Mendelian randomisation analyses of short sleep, insomnia symptoms, total sleep duration, long sleep, snoring, daytime sleepiness and morning chronotype with a broad range of health-related phenotypes. We assessed the association between the genetic predisposition to these traits and the occurrence of 702 health-related phenotypes, using summary statistics of the largest genome-wide association studies in European individuals. Results that were significant (multiple comparisons: False Discovery Rate) and valid (robust genetic instruments, unaffected by horizontal pleiotropy) were validated using data from the second largest European genome-wide association study. Genetically determined short sleep was associated with increased risks of attention-deficit/hyperactivity disorder and neuroticism, musculoskeletal conditions, asthma and gastroesophageal reflux and lower educational attainment. Genetically determined insomnia symptoms showed associations with increased risk of coronary artery disease, major depression and osteoarticular disease. Genetically determined long sleep was linked to higher risk of iron deficiency anaemia and lower bone mineral density. Genetic predisposition to snoring was associated with more falls, greater body mass and higher low-grade inflammation. Genetically determined morning chronotype was related to higher vitamin D levels and lower risk of irritable bowel syndrome. No associations were found for daytime sleepiness. Overall, these findings indicate that genetically determined short sleep duration and insomnia symptoms are associated with mental and neurological problems, cardiovascular disease and musculoskeletal disorders, suggesting a potentially preventive, causal role of healthy sleeping patterns on chronic disease., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Covalent functionalization of polymeric nanoparticles prepared from nano-emulsion templates for gene silencing and antioxidant delivery at neuronal level

  • Bel Esteve, Marta
  • Carrasco, Marc
  • Moral, Nuria
  • Aviñó, Ana
  • Fàbrega, Carme
  • eritja, ramon
  • del Río, José Antonio
  • Duran, Jordi
  • Fornaguera, Cristina
  • Rodriguez-Abreu, Carlos
  • Grijalvo, Santiago
Poly(lactic-co-glycolic acid) (PLGA)-based polymeric nanoparticles (PLGA NPs) have proven to be effective as potential drug delivery systems. The presence of carboxylate groups on their surface facilitates the development of multifunctional NPs enhancing therapeutic efficacy through synergetic effects. Our study describes the preparation of PLGA NPs using oil-in-water polymeric nano-emulsions, generated via a phase inversion composition low-energy emulsification method. Rosmarinic acid (RA), a phytochemical with neuroprotective effects, and an antisense oligonucleotide (ASO) were selected respectively as a phytochemical to be entrapped and as a ligand to decorate the surface of PLGA nanoparticles respectively, aiming to enhance ASO delivery to neuronal cells. Physicochemical characterization confirmed that RA and ASO incorporation preserved colloidal stability, with no adverse effect on particle size, surface charge, or morphology. In vitro-controlled release experiments showed a cumulative RA release of ca. 12% over 24 h governed by a semi-Fickian diffusion mechanism after adjusting to different equation models. Importantly, RA entrapment displayed measurable radical scavenging capacity, leading to a EC50 of 76 ± 0.9 μg·mL−1. Cell culture experiments confirmed biocompatibility in both a non-cancer cell line (HEK293) and neuroblastoma cell model (SH-SY5Y). Uptake studies revealed efficient internalization of PLGA NPs by SH-SY5Y cells and primary murine neurons, promoting gene silencing of luciferase expression (53.7 ± 7.9%). Together, these results show a modular PLGA nanoplatform that enables the simultaneous incorporation of an antioxidant payload and a covalently grafted antisense oligonucleotide, allowing independent assessment of redox modulation and gene silencing in neuronal models., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Polymeric nanoparticles for liver-targeted pituitary tumor-transforming gene 1 silencing in rats with chronic liver disease

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Casals Mercadal, Gregori
  • Faneca Farrés, Joana
  • Macias-Herranz, Manuel
  • Boix, Loreto
  • Fundora Suarez, Yiliam
  • Morales-Ruiz, Manuel
  • Garcia-Villoria, Judit
  • Fornaguera, Cristina
  • Borrós, Salvador
  • Jiménez, Wladimiro
Pituitary tumor transforming gene 1 (Pttg1) is upregulated in cirrhosis and hepatocarcinoma (HCC). We assessed the therapeutic effect of liver-targeted Pttg1 siRNA Retinol (Ret) pBAE nanoparticles (NPs) to treat these disturbances. Fibrosis was induced in Wistar rats by carbon tetrachloride inhalation and HCC by diethylnitrosamine injection. Ret pBAE NPs accumulated in hepatic tissue, close to zones positive for αSMA staining. Pttg1 interference increased mean arterial pressure, reduced portal hypertension and decreased collagen accumulation and inflammatory infiltrate in fibrotic rats. In HCC rats, Pttg1 silencing reduced liver to body weight ratio and hepatic proliferation and increased hepatic ATP production and serum glucose. This therapy effectively mitigated liver fibrosis and HCC progression in experimental models. The feasibility of this treatment was also demonstrated in human derived hepatic stellate cells and in ex vivo human cirrhotic livers underscoring the therapeutic potential of Pttg1 siRNA Ret pBAE NPs in addressing liver fibrosis and HCC., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering oncogene-targeted anisamide-functionalized pBAE nanoparticles as efficient lung cancer antisense therapies

  • Fornaguera, Cristina
  • Torres-Coll, Antoni
  • Olmo, Laura
  • Garcia-Fernandez, Coral
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
Non-small cell lung cancer (NSCLC) is one of the leading causes of worldwide death, mainly due to the lack of efficient and safe therapies. Currently, NSCLC standard of care for consist on the use of traditional chemotherapeutics, non-selectively distributed through the whole body, thus causing severe side effects while not achieving high efficacy outcomes. Consequently, the need of novel therapies, targeted to modify specific subcellular routes aberrantly expressed only in tumor cells is still urgent. In this context, the delivery of siRNAs that can know-down overexpressed oncogenes, such as mTOR, could become the promised targeted therapy. However, siRNA effective delivery remains a challenge due to its compromised stability in biological fluids and its inability to cross biological and plasmatic membranes. Therefore, polymeric nanoparticles that efficiently encapsulate siRNAs and are selectively targeted to tumor cells could play a pivotal role. Accordingly, we demonstrate in this work that oligopeptide end-modified poly(beta aminoester) (OM-pBAE) polymers can efficiently complex siRNA in small nanometric particles using very low polymer amounts, protecting siRNA from nucleases attack. These nanoparticles are stable in the presence of serum, advantageous fact in terms of in vivo use. We also demonstrated that they efficiently transfect cells in vitro, in the presence of serum and are able to knock down target gene expression. Moreover, we demonstrated their antitumor efficacy by encapsulating mTOR siRNA, as a model antisense therapy, which showed specific lung tumor cell growth inhibition in vitro and in vivo. Finally, through the addition of anisamide functionalization to the surface of the nanoparticles, we proved that they become selective to lung tumor cells, while not affecting healthy cells. Therefore, our results are a first step in the discovery of a tumor cell-targeted efficient silencing nanotherapy for NSCLC patients survival improvement., info:eu-repo/semantics/publishedVersion